ValuEngine cut shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a hold rating to a sell rating in a research note published on Tuesday.
Separately, HC Wainwright reiterated a buy rating and set a $25.00 price objective on shares of Oramed Pharmaceuticals in a research report on Thursday, October 5th.
Oramed Pharmaceuticals (NASDAQ ORMP) traded down $0.77 during mid-day trading on Tuesday, reaching $7.94. 240,400 shares of the company were exchanged, compared to its average volume of 43,205. Oramed Pharmaceuticals has a twelve month low of $5.82 and a twelve month high of $11.34.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
What are top analysts saying about Oramed Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Oramed Pharmaceuticals Inc. and related companies.